The BET inhibitor/degrader ARV-825 prolongs the growth arrest response to Fulvestrant + Palbociclib and suppresses proliferative recovery in ER-positive breast cancer

Overview of attention for article published in Frontiers in oncology, January 2023

Altmetric Badge

About this Attention Score

Good Attention Score compared to outputs of the same age (67th percentile)
High Attention Score compared to outputs of the same age and source (89th percentile)

Mentioned by

twitter: 7 X users

Citations

dimensions_citation: 13 Dimensions

Readers on

mendeley: 11 Mendeley

Summary X Dimensions citations

So far, Altmetric has seen 8 X posts from 7 X users, with an upper bound of 33,005 followers.

RT @Trankill34: Frontiers | The BET inhibitor/degrader ARV-825 prolongs the growth arrest response to Fulvestrant + Palbociclib and suppres…

09 Feb 2023

Reply Repost Favourite

The BET inhibitor/degrader ARV-825 prolongs the growth arrest response to Fulvestrant + Palbociclib and suppresses proliferative recovery in ER-positive breast cancer https://t.co/qzZWEVokay https://t.co/218m862cAm

07 Feb 2023

Reply Repost Favourite

RT @Trankill34: Frontiers | The BET inhibitor/degrader ARV-825 prolongs the growth arrest response to Fulvestrant + Palbociclib and suppres…

06 Feb 2023

Reply Repost Favourite

Frontiers | The BET inhibitor/degrader ARV-825 prolongs the growth arrest response to Fulvestrant + Palbociclib and suppresses proliferative recovery in ER-positive breast cancer @FrontiersIn https://t.co/R141OUAOI9

06 Feb 2023

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity, including 4 additional X posts.